Treats hypertension. ANDA 206641, held by Zydus Pharms. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 206641 (Diltiazem Hydrochloride), held by Zydus Pharms, was first approved by FDA on Aug 11, 2017, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Hypertension: Tiadylt ER capsules are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications. Chronic Stable Angina: Tiadylt ER capsules are indicated for the treatment of chronic stable angina.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 11, 2017 | Original application | Approved |
| Diltiazem Hydrochloride120MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride180MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride240MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride300MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride360MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride420MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Jun 26, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 11, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters